Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) just unveiled an update.
On November 13, 2025, Eupraxia Pharmaceuticals announced additional 52-week follow-up data from its RESOLVE trial for treating eosinophilic esophagitis (EoE) with EP-104GI. The data showed consistent and durable symptom relief in Cohort 6, with 67% of patients in clinical remission at 52 weeks, and no serious adverse events reported. These results highlight EP-104GI’s potential as a once-a-year treatment, aligning with routine disease management and offering a promising alternative to current EoE therapies that struggle with long-term adherence.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
Eupraxia Pharmaceuticals’ overall score reflects its challenging financial position with no revenue and ongoing net losses. While recent positive trial results and operational progress are encouraging, the company’s reliance on external financing and high liabilities pose significant risks. Technical indicators suggest some positive momentum, but valuation challenges persist due to lack of profitability. The strengthened financial position through capital raise is a mitigating factor but does not offset the underlying financial instability.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Victoria, British Columbia, Canada. The company focuses on developing locally delivered, extended-release products using its proprietary Diffusphere technology, which aims to optimize drug delivery for applications with significant unmet needs. Eupraxia’s current projects include treatments for inflammatory gastrointestinal diseases and pain, with potential applications in oncology and infectious diseases.
Average Trading Volume: 50,622
Technical Sentiment Signal: Buy
Current Market Cap: C$478.4M
For a thorough assessment of EPRX stock, go to TipRanks’ Stock Analysis page.